Company: BGLC
Filing Date: 2025-08-18
Form Type: 10-Q
Source: 0001477932-25-006023
Chunk: 4

Company: BioNexus Gene Lab Corp
Filing Date: 2025-08-18
Form: 10-Q
Item: Part I, Item 1
Chunk 4
---
 (56,136)  (119,499)  (100,433)Provision for expected credit losses   -   -   (40,124)  (120,469)TOTAL OPERATING EXPENSES  (1,188,776)  (759,657)  (2,242,107)  (1,405,563)                 (LOSS)/PROFIT FROM OPERATIONS  (611,293)  259,168   (1,229,711)  180,140                  FINANCE COSTS  (4,879)  (4,480)  (9,788)  (9,141)                 (LOSS)/PROFIT BEFORE TAX  (616,172)  254,688   (1,239,499)  170,999                  Tax expense  -   (55,584)  -   (75,652)                 NET (LOSS)/PROFIT ATTRIBUTABLE TO COMMON SHAREHOLDERS  $(616,172) $199,104  $(1,239,499) $95,347                  Other comprehensive income/(loss)                Foreign currency translation gain/(loss)  367,078   2,463   439,237   (207,445)                 COMPREHENSIVE (LOSS)/PROFIT $(249,094) $201,567  $(800,262) $(112,098)                 Earnings per share - Basic and diluted  (0.343)  0.113   (0.690)  0.054 Weighted average number of common stocks outstanding, Basic and Diluted #  1,796,597   1,766,766   1,796,597   1,766,766 

# Weighted average shares outstanding and per share amount have been adjusted for the periods shown to reflect the 10-for-1 reverse stock split effected on April 7, 2025 and the 12-for-1 reverse stock split effected on July 20, 2023, on a retroactive basis as described in Note 12.

See accompanying notes to the condensed consolidated financial statements.

 6Table of Contents

BIONEX